poisar

Stock

Aardvark Therapeutics, Inc. AARD

$6.33-0.86%

Overview

AARD market data

Price History

AARD price chart

Valuation & Profitability

Twelve Data
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$2.93
Diluted earnings per share over the trailing twelve months.
Beta
4.01
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$3.35 – $17.94
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $141.8 · P/B 2.68.

Company news

10 captured
HC Wainwright & Co. Reiterates Neutral on Aardvark Therapeutics, Announces $6 Price TargetBenzinga · Jul 20, 2026, 11:20 AM
B. Riley Securities Maintains Buy on Aardvark Therapeutics, Lowers Price Target to $7Benzinga · May 15, 2026, 5:03 PM
This Unity Bancorp Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For FridayBenzinga · May 15, 2026, 3:49 PM
BTIG Downgrades Aardvark Therapeutics to NeutralBenzinga · May 15, 2026, 2:50 PM
FDA Halts Aardvark Therapeutics Rare Disease StudyBenzinga · May 15, 2026, 2:30 PM
This BWX Technologies Analyst Turns Bullish; Here Are Top 3 Upgrades For FridayBenzinga · May 15, 2026, 1:00 PM
This Alumis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For FridayBenzinga · May 15, 2026, 12:30 PM
Morgan Stanley Downgrades Aardvark Therapeutics to Underweight, Lowers Price Target to $3Benzinga · May 15, 2026, 11:00 AM
Aardvark Therapeutics Says FDA Places Full Clinical Hold On Its Investigational New Drug Application For ARD-101 Related To Prior Announced Voluntary PauseBenzinga · May 14, 2026, 8:04 PM
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate– Hagens BermanGlobenewswire Inc · May 14, 2026, 7:15 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock